2025-05-30 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals Inc. (RXRX) based on the data you provided, presented in English with a focus on key figures and straightforward explanations:

## RXRX (Recursion Pharmaceuticals Inc.) Analysis

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover and develop novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

*   **RXRX Cumulative Return:** -60.92%
*   **VOO Cumulative Return:** 14.72%
*   **Absolute Divergence:** -75.64%
*   **Relative Divergence:** 0.6 (On a scale where 0 represents the historical minimum divergence and 100 represents the maximum divergence, RXRX is near its worst performance relative to VOO).

**Analysis:** RXRX has significantly underperformed the S&P 500 (VOO). The large negative divergence suggests substantial relative weakness. The Relative Divergence of 0.6 indicates that the current underperformance is near the bottom end of its historical range relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year        | CAGR     | MDD      | Alpha    | Beta   | Cap(B) |
| ----------- | -------- | -------- | -------- | ------ | ------ |
| 2021-2023   | 5.0%   | 73.6%  | 1.0%   | -0.0 | 4.0    |
| 2022-2024   | 0.0%   | 73.6%  | -16.0%  | 0.1  | 2.7    |
| 2023-2025   | -9.0%  | 73.6%  | -39.0%  | 0.1  | 1.8    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) has declined over the analyzed periods, turning negative in the most recent period (2023-2025).
*   **MDD:** The Maximum Drawdown (MDD) remains consistently high at 73.6% across all periods, indicating significant risk.
*   **Alpha:** The Alpha is negative in the later periods, showing underperformance relative to the benchmark.
*   **Beta:** The Beta is relatively low, indicating that the stock's price does not move much with the market.
*   **Cap(B):** Market capitalization has been declining over the years.

### 2. Recent Price Action

*   **Last Price:** 4.45
*   **Previous Close:** 4.395
*   **Change:** 1.25%
*   **5-day Moving Average:** 4.292
*   **20-day Moving Average:** 4.4952
*   **60-day Moving Average:** 5.3207

**Analysis:**  The stock price closed higher than its previous close with a notable change. The price is currently below the 20-day and significantly below the 60-day moving averages, suggesting a potential downtrend, although it's trading above the 5-day moving average, which could signal a short-term upward trend.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.366 (Low Risk)
*   **RSI:** 51.43
*   **PPO:** 0.6612
*   **Hybrid Signal:** cash_3%_Buy 80% of cash (483 shares - Caution - MRI:0.37)
*   **Recent (20-day) Relative Divergence Change:** -0.1 (Negative - short-term decline)
*   **Expected Return (%):** -2371.1

**Analysis:** The MRI indicates a low-risk environment for the stock. The RSI is neutral. The PPO is slightly positive. The hybrid signal suggests caution, while the significant negative expected return is alarming, implying a very pessimistic long-term outlook compared to the S&P 500. The negative change in relative divergence confirms a recent short-term decline. The last market data {'price': 4.45, 'previousClose': 4.395, 'change': 1.25} doesn't reflect any abrupt changes and could be considered a standard market fluctuation.

### 4. Recent News & Significant Events

*   **May 27, 2025:** Major business developments, regulatory changes, or market events.
*   **May 26, 2025:** Analyst discussions on recent performance and industry/economic context.
*   **May 30, 2025:** Notable stock volatility due to recent news, earnings, or executive actions.
*   **May 29, 2025:** Market experts highlighting risks and opportunities, advising monitoring of news and announcements.

**Analysis:** The news suggests recent volatility and uncertainty surrounding RXRX, with analysts closely monitoring the company's performance and potential risks and opportunities.

### 5. Recent Earnings Analysis

| 날짜         | EPS   | 매출       |
| ------------ | ----- | ---------- |
| 2025-05-05   | -0.5  | 0.01 B$    |
| 2024-11-06   | -0.34 | 0.03 B$    |
| 2024-08-08   | -0.4  | 0.01 B$    |
| 2024-05-09   | -0.39 | 0.01 B$    |
| 2025-05-05   | -0.39 | 0.01 B$    |

**Analysis:** RXRX has consistently reported negative Earnings Per Share (EPS) across the listed quarters. Revenue has been relatively low and inconsistent.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
| ------------ | ------- | ------------- |
| 2025-03-31   | $0.01B | -47.31%       |
| 2024-12-31   | $0.00B | -183.62%      |
| 2024-09-30   | $0.03B | 53.69%        |
| 2024-06-30   | $0.01B | 36.14%        |
| 2024-03-31   | $0.01B | 17.23%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE       |
| ------------ | ------- | --------- |
| 2025-03-31   | $0.93B | -21.68%   |
| 2024-12-31   | $1.03B | -17.29%   |
| 2024-09-30   | $0.52B | -18.27%   |
| 2024-06-30   | $0.58B | -16.69%   |
| 2024-03-31   | $0.40B | -22.78%   |

**Analysis:**

*   **Revenue:** Revenue is low and has fluctuated.
*   **Profit Margin:** Profit margins have been mostly negative, indicating a struggle to generate profit from revenue.
*   **Equity:** Equity has fluctuated, increasing but then decreasing in recent quarters.
*   **ROE:** Return on Equity (ROE) has been consistently negative, indicating poor profitability relative to equity.

### 7. Overall Assessment

RXRX has underperformed the S&P 500 significantly. Recent news suggests potential volatility and uncertainty. The company is currently operating at a loss, with negative EPS, profit margins, and ROE. Technical indicators provide mixed signals, but the overwhelmingly negative expected return raises serious concerns. While the Market Risk Indicator (MRI) suggests a low-risk environment, this might be misleading given the underlying financial challenges. The analyst recommendations to monitor company news, given the recent volatility, imply the need for a cautious approach.
